Pfizer Limited

NSE PFIZER.NS

Pfizer Limited Capital Expenditure for the year ending March 31, 2024: USD -2.27 M

Pfizer Limited Capital Expenditure is USD -2.27 M for the year ending March 31, 2024, a 71.29% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Pfizer Limited Capital Expenditure for the year ending March 31, 2023 was USD -7.91 M, a -292.10% change year over year.
Pfizer Limited Capital Expenditure for the year ending March 31, 2022 was USD -2.02 M, a 16.59% change year over year.
Pfizer Limited Capital Expenditure for the year ending March 31, 2021 was USD -2.42 M, a -7.85% change year over year.
Pfizer Limited Capital Expenditure for the year ending March 31, 2020 was USD -2.24 M, a -246.89% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NSE: PFIZER.NS

Pfizer Limited

CEO	Ms. Meenakshi Nevatia
IPO Date	July 1, 2002
Location	India
Headquarters	The Capital
Employees	1,721
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, respiratory, and vitamins/minerals/nutrients. It sells its products through a network of independent distributors primarily under various brand names. The company was incorporated in 1950 and is headquartered in Mumbai, India.

Key trends

Past 5 years